EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieKlinische Studie (Phase III)VergleichsstudieOpen Access · CC BY 4.0

Patient-Reported Tolerability of Selpercatinib Compared to Cabozantinib/Vandetanib: A Secondary Analysis of the LIBRETTO-531 Randomized-Controlled Trial in RET -Mutant Medullary Thyroid Cancer

Rossella Elisei, Lori J Wirth iD, Jaume Capdevila, Ana Oliveira Hoff, Makoto Tahara, Eric J Sherman, Mimi I Hu, Ming-Hua Ge, Jonathan Wadsley, Fernanda Vaisman, Katerina Kopeckova, Jolanta Krajewska und 9 weitere

Thyroid® · 2025

DOI: 10.1177/10507256251367352 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Thyroid®, 2025. Verfasst von Rossella Elisei und 20 weiteren Autor:innen. Beteiligte Einrichtung: Endocrine Unit, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy. Hauptthemen laut MEDLINE: Anilides, Carcinoma, Neuroendocrine, Piperidines, Pyrazoles. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 18 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Progression-free survival (PFS) may not fully capture the impact of treatment on patients, especially in cancers with longer natural histories and thus, could be complemented by robust measures of patient-reported tolerability (PRT). We report the use of a novel, quantifiable PRT metric as a multiplicity-controlled endpoint to support regulatory and clinical decision-making for selpercatinib use. Comparative PRT was assessed in LIBRETTO-531 (NCT04211337), a randomized phase 3 trial of selpercatinib versus vandetanib/cabozantinib (control) in advanced RET -mutant medullary thyroid cancer (MTC). Patients and Methods: Patients were self-administered the single Functional Assessment of Cancer Therapy item GP5: “I am bothered by side effects” weekly, and scores were dichotomized into “low” (0–2) and “high” (3–4) side-effect burden. PRT measured the proportion of time on treatment (PTT) with “high” side-effect burden for each patient. Comparative PRT was tested at a two-sided significance level of 0.05, conditional on achieving significance for efficacy endpoints. Complementary patient-reported outcomes included health-related quality of life (HRQoL) and symptomatic adverse events self-administered at baseline and at different intervals post-baseline during treatment period.

Results

In the tolerability evaluable population (N = 242; selpercatinib n = 161 and control n = 81 [56 received cabozantinib, 25 received vandetanib]), patients on selpercatinib had significantly better PRT with lower PTT with “high side-effect burden” than control (8% vs. 24%, p < 0.0001). Post-baseline compliance rates for PRO questionnaires were generally greater than 80% in both treatment groups. Patients on selpercatinib reported significantly less PTT with HRQoL impairment across physical (36% vs. 52%), role (2% vs. 11%), cognitive (4% vs. 8%), emotional (6% vs. 11%), and social (2% vs. 8%) function (all p < 0.01); and significantly less PTT with severe diarrhea (5% vs. 38%), fatigue (6% vs. 21%), taste change (3% vs. 15%), decreased appetite (2% vs. 15%), and hand-foot syndrome (2% vs. 9%) (all p < 0.001).

Conclusion

This study demonstrated superior PRT for selpercatinib compared with control in patients with RET -mutant MTC, further supporting selpercatinib use as the first-line treatment for patients with advanced RET -mutant MTC. Comparative PRT deserves further adoption as a complement to traditional endpoints in future randomized-controlled trials.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AnilidesCarcinoma, NeuroendocrinePiperidinesPyrazolesPyridinesQuinazolinesThyroid NeoplasmsAdultAgedFemaleHumansMaleMiddle AgedMutationPatient Reported Outcome MeasuresProtein Kinase InhibitorsProto-Oncogene Proteins c-retQuality of LifeTreatment Outcome

Stichwörter der Autor:innen

RET-mutant medullary thyroid cancerpatient-reported outcomequality of lifeselective RET inhibitionselpercatinibtolerability endpoint

Substanzen

AnilidescabozantinibPiperidinesProtein Kinase InhibitorsProto-Oncogene Proteins c-retPyrazolesPyridinesQuinazolinesRET protein, humanselpercatinib

Autor:innen und Institutionen

  • Endocrine Unit, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy.
  • Cancer Center, Massachusetts General Hospital, Boston, Massachusetts, USA.
  • Medical Oncology Department, Vall d'Hebron Institute of Oncology, Universitat Autònoma de Barcelona, Barcelona, Spain.
  • Department of Endocrinology, Instituto do Câncer do Estado de São Paulo, Universidade de São Paulo, São Paulo and Instituto D' OR de Pesquisa e Ensino, São Paulo, Brazil.
  • Department of Head and Neck Medical Oncology, National Cancer Center Hospital East, Kashiwa, Japan.
  • Department of Medical Oncology, Memorial Sloan Kettering Cancer Center, New York, New York, USA.

ORCID-Profile: Lori J Wirth, Julien Hadoux

Zitieren

APA

Elisei, R., Wirth, L. J., Capdevila, J., Hoff, A. O., Tahara, M., Sherman, E. J., Hu, M. I., Ge, M. H., Wadsley, J., Vaisman, F., Kopeckova, K., Krajewska, J., Olvera, D., Churchill, C., Maeda, P., Gilligan, A. M., Lin, Y., Payakachat, N., Robinson, B., …, & Brose, M. S. (2025). Patient-Reported Tolerability of Selpercatinib Compared to Cabozantinib/Vandetanib: A Secondary Analysis of the LIBRETTO-531 Randomized-Controlled Trial in RET -Mutant Medullary Thyroid Cancer. Thyroid®. https://doi.org/10.1177/10507256251367352

Vancouver

Elisei R, Wirth LJ, Capdevila J, Hoff AO, Tahara M, Sherman EJ, et al. Patient-Reported Tolerability of Selpercatinib Compared to Cabozantinib/Vandetanib: A Secondary Analysis of the LIBRETTO-531 Randomized-Controlled Trial in RET -Mutant Medullary Thyroid Cancer. Thyroid®. 2025. doi:10.1177/10507256251367352

BibTeX
@article{Elisei2025,
  author = {Elisei, Rossella and Wirth, Lori J and Capdevila, Jaume and Hoff, Ana Oliveira and Tahara, Makoto and Sherman, Eric J and Hu, Mimi I and Ge, Ming-Hua and Wadsley, Jonathan and Vaisman, Fernanda and Kopeckova, Katerina and Krajewska, Jolanta and Olvera, Dinorath and Churchill, Collin and Maeda, Patricia and Gilligan, Adrienne M and Lin, Yan and Payakachat, Nalin and Robinson, Bruce and Hadoux, Julien and Brose, Marcia S},
  title = {Patient-Reported Tolerability of Selpercatinib Compared to Cabozantinib/Vandetanib: A Secondary Analysis of the LIBRETTO-531 Randomized-Controlled Trial in RET -Mutant Medullary Thyroid Cancer},
  journal = {Thyroid®},
  year = {2025},
  doi = {10.1177/10507256251367352}
}
Kostenlos starten →